Jun 19, 2019   SOURCE: PR NewsWire

Norovirus: Worldwide Market Spotlight, 2018 Featuring Top 10 Companies & Drugs

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Norovirus" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, key upcoming events, and an epidemiological overview.

Key Takeaways

    --  Worldwide, about one out of every five cases of acute gastroenteritis is
        associated with norovirus. Norovirus is responsible for approximately
        685 million cases of gastroenteritis every year.
    --  Globally, norovirus is estimated to cause approximately 200,000 deaths
        annually, with at least 50,000 being children, mainly in developing
        countries.
    --  There are four clinical candidates in development for norovirus; two in
        Phase I and two in Phase II. The majority of clinical candidates
        currently in the pipeline for norovirus are vaccines. These are
        administered via the oral, intranasal, and intramuscular routes.
    --  Topline Phase IIb trial results for Monovalent Norovirus VLP Vaccine is
        the only high-impact upcoming event for drugs in the norovirus space.
    --  The overall likelihood of approval of a Phase I antiviral asset is
        16.2%, and the average probability a drug advances from Phase III is
        75.9%. Drugs, on average, take 8.6 years from Phase I to approval,
        compared to 9 years in the overall infectious disease space.
    --  The clinical trials distribution across Phase I-III indicates that the
        vast majority of trials for norovirus have been in the early and
        mid-phases of development, with 91% of trials in Phase I-II, and only 9%
        in Phase III.
    --  Takeda has the highest number of completed and planned clinical trials
        for norovirus, with eight trials in each category. Takeda also leads
        industry sponsors with by far the highest overall number of clinical
        trials for norovirus, followed by Vaxart.

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

EPIDEMIOLOGY
Norovirus outbreaks
Challenges for vaccine development

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Overview of pipeline drugs for norovirus in the US
Figure 2: Pipeline drugs for norovirus, by company
Figure 3: Pipeline drugs for norovirus, by drug type
Figure 4: Pipeline drugs for norovirus, by classification
Figure 5: Key upcoming events in norovirus
Figure 6: Probability of success in the norovirus pipeline
Figure 7: Clinical trials in norovirus
Figure 8: Top 10 drugs for clinical trials in norovirus
Figure 9: Top 10 companies for clinical trials in norovirus
Figure 10: Norovirus trials status
Figure 11: Norovirus trials sponsors, by phase

LIST OF TABLES
Table 1: Pipeline drugs for norovirus in the US

For more information about this report visit https://www.researchandmarkets.com/r/hw3ls

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/norovirus-worldwide-market-spotlight-2018-featuring-top-10-companies--drugs-300871302.html

SOURCE Research and Markets